distortedthehmtn
Ignore the user
- Joined
- Dec 5, 2025
- Posts
- 31
- Reputation
- 12
Height-Promoting Treatments in Adolescence: FGFR3 Inhibitors, GH, and Anabolics
Executive Summary: New agents targeting growth-plate biology (e.g. FGFR3 inhibitors) and traditional therapies (growth hormone, androgens) have been explored to increase final adult height. FGFR3 inhibitors (vosoritide, infigratinib) work by blocking FGFR3 signaling to boost chondrocyte proliferation. In achondroplasia, vosoritide yields ~1.6–2.0 cm/year excess growth and ~9 cm extra over ~4.5 years (phase 2); infigratinib (oral) shows ~2.5 cm/yr gain at optimal dose. Human GH stimulates IGF-1 and growth plate activity; high-dose GH (0.3–0.4 mg/kg/week) in idiopathic short stature (ISS) can add ~4–9 cm to adult height, though gains tend not to exceed genetic potential. Anabolic steroids (e.g. oxandrolone) modestly improve height when added to GH (e.g. +2–3 cm in Turner syndrome) but cause virilizing effects and premature epiphyseal closure. All interventions must stop once growth plates fuse. Safety concerns are agent-specific: FGFR3 inhibitors can cause hypotension or metabolic shifts; GH therapy can trigger slipped capital femoral epiphysis or glucose intolerance; androgens carry hepatic, lipid and virilization risks. These treatments are approved only for defined conditions (e.g. GH deficiency, achondroplasia, Turner), not for non-pathologic short stature. Combining therapies (GH+anabolic in Turner; GH+GnRH analogs in puberty delay) is sometimes used. Baseline and periodic monitoring (bone age, IGF-1, lipids, BP, blood counts/liver tests) are needed. Major evidence gaps include long-term adult-height outcomes (especially for FGFR3 inhibitors) and effects in non-dwarfism short stature. Anecdotally, forum discussions stress that without growth-plate openness or deficiency, height gains are generally limited (often ≤ 2–3 inches total).
Mechanisms of Action
FGFR3 Inhibitors: FGFR3 normally suppresses endochondral bone growth. Achondroplasia is due to FGFR3 gain-of-function; inhibiting this pathway (by CNP analogues or FGFR3 tyrosine kinase inhibitors) lifts this brake. Vosoritide (CNP analog) activates natriuretic-peptide receptor B to reduce FGFR3 signaling. Infigratinib and similar drugs block the FGFR3 tyrosine kinase. The net effect is increased chondrocyte proliferation and height velocity.
Growth Hormone (hGH): Recombinant GH increases production of IGF-1 (especially in the liver), which stimulates chondrocyte proliferation in growth plates. GH also has direct effects on bone and cartilage. This axis is endogenous and GH’s anabolic effects on bone underlie its use in GH deficiency and other growth disorders.
Anabolic Steroids (Androgens): Androgens (e.g. testosterone derivatives) bind the androgen receptor to promote protein synthesis and growth. In prepubertal boys with delayed puberty, testosterone can trigger a growth spurt (via GH/IGF-1); in girls (e.g. Turner syndrome), weak androgens (oxandrolone) augment GH therapy. However, androgens are aromatized to estrogen, which accelerates epiphyseal fusion. Thus, androgens both stimulate and eventually terminate growth plate activity.
Efficacy Evidence (Final Height Gain)
Achondroplasia (FGFR3 inhibitors): Vosoritide trials (phase 3, 1 year) show ~1.6 cm mean height gain vs placebo (annualized velocity ~5.96 vs 4.22 cm/yr). Open-label extension data suggest ~9 cm extra height vs natural history over ~4.5 years. Long-term anecdotal reports (company press) cite ~13–14 cm over 8–10 years, but final height impact is still under study. Infigratinib (oral) in a recent NEJM trial (children 3–11 yr) increased height z-score by +0.54 over 18 months, corresponding to +2.5 cm/yr velocity at the highest dose. These are among the highest published gains in achondroplasia.
Idiopathic Short Stature / GH Deficiency (hGH): In GH-deficient children, GH therapy usually normalizes growth (adult height near target). In non-deficient short children, results vary. A large retrospective series (123 ISS children on 0.32 mg/kg/week) found average adult height ~–0.7 SDS (normalized) and a gain of ~9.5 cm (males) vs controls. Meta-analyses of RCTs in ISS show modest final height gains (typically ~4–6 cm over untreated). Gains correlate with dose and pubertal timing. In Turner syndrome, GH alone adds ~+8–10 cm. Combining GH with an anabolic (oxandrolone) further adds ~2–3 cm.
Anabolic (e.g. Oxandrolone): In Turner girls on GH, adding oxandrolone yields a mean final height increase of ~2.7 cm. Without GH (e.g. in constitutional delay), oxandrolone alone has no clear benefit on adult height. High-dose testosterone in prepubertal or pubertal boys can provoke a temporary growth spurt but generally leads to earlier closure and no net gain.
Safety Profiles & Adverse Effects
FGFR3 inhibitors: Vosoritide: Common adverse effects include injection-site reactions (erythema, pain, swelling) and transient hypotension. In trials, ~13% of vosoritide-treated children had brief blood pressure drops (vs 5% placebo); symptomatic dizziness/vomiting occurred in ~3%. Other events (vomiting, arthralgia) occurred in 5–10%. Long-term safety is still being defined, but trials report normal bone maturation and no serious cardiac or metabolic issues yet. Infigratinib: Generally mild side effects: headache, nausea, vomiting, limb pain were frequent. Hyperphosphatemia (a known effect of FGFR inhibitors) occurred in a few cases but was mild and manageable. No ocular or major bone toxicity was reported in 18 months.
hGH: Generally well tolerated in short-term. Common mild effects: joint pain, peripheral edema, injection-site pain. Elevated IGF-1 can cause benign intracranial hypertension (headache/blurred vision) in <1–2%. Slipped capital femoral epiphysis (SCFE) is a known rare complication (often with rapid growth, ~0.5–1% risk). GH can induce insulin resistance; new onset diabetes is very rare. Theoretical concerns about cancer risk have not been confirmed in long-term studies. Absolute contraindications: active malignancy, uncontrolled diabetes, intracranial hypertension. GH is also used cautiously in Prader–Willi (due to respiratory risk).
Anabolic steroids: Oxandrolone and other androgens cause virilizing effects: deepening voice, hirsutism, acne (noted in ~10–20% of girls on oxandrolone). Hepatotoxicity (elevated liver enzymes) is a concern with oral 17α-alkylated steroids. Lipid changes (↓HDL) and potential cardiovascular effects must be watched. Most critically, androgens cause premature epiphyseal closure through estrogen conversion, limiting final height. Therefore dosing must be carefully timed and often stopped before puberty. In Turner studies, oxandrolone was used only until age ~12–13 to avoid these effects.
Dosing Regimens
FGFR3 inhibitors: Vosoritide (Voxzogo): 15 µg/kg subcutaneously once daily (dose adjusted by weight every ~3–6 months). Continued daily dosing until growth plate closure. Phase 2 data suggest this dose in 5–10 yr-olds provides roughly +2 cm/year extra. Infigratinib: 0.25 mg/kg orally once daily (the highest dose in trials). Lower doses had less effect. Other FGFR3 compounds (TAK-536, etc) are experimental, dosing not established.
Human GH: Typical pediatric dosing is 0.16–0.3 mg/kg/week, divided into daily or nightly injections. In ISS or Turner, 0.3–0.35 mg/kg/week is often used to maximize height gain. Dosing is adjusted by weight as the child grows. Therapy usually continues until near-final height (bone age ~14–16 in girls, 16–18 in boys). GH must be prescribed under medical supervision.
Oxandrolone: In published Turner trials, oxandrolone was given ~0.03–0.05 mg/kg/day orally (5–10 mg/day) starting around age 9–11, added to GH. It was usually discontinued by mid-puberty. Other anabolic agents (testosterone, nandrolone, etc.) have no standard dosing for stature enhancement; anabolic steroid use outside guideline contexts is unsanctioned.
Timing & Growth Plate Status
All growth-promoting therapies require open epiphyses. Treatment is generally only effective while the physes are active. In practice:
Assess bone age by X-ray: if bone age is significantly less than chronological, there may be more growth potential.
FGFR3 inhibitors: Indicated when growth plates are open (FDA label: ages ≥5 with open plates). Expert consensus says “maximize time” by starting as early as possible and continue until plates fuse.
GH/Anabolics: Similarly, begun in childhood or early puberty. For example, in Turner syndrome, GH±oxandrolone is typically started at ages 6–12 and stopped when growth near completion.
Pubertal status: High estrogen/testosterone accelerates closure. Therapies like GnRH analogs (not FGFR3/GH/anabolic but worth noting) can delay puberty to prolong growth. If puberty is advanced, the window narrows. Adolescents (e.g. ≥15 yr) with near-fused plates may gain only a few cm at most. In short, once growth plates are closed, height gain >2–3 cm is highly unlikely.
Safety Monitoring
FGFR3 inhibitors (Vosoritide, etc.): Baseline and periodic blood pressure (risk of hypotension), and growth velocity/height measurements every 3–6 months. Monitor height/weight and adjust dose accordingly. Annual bone age X-ray helps track progress. Lab tests: No mandated labs for vosoritide aside from BP, but check chemistries if clinical (infigratinib needs phosphate monitoring due to potential hyperphosphatemia).
Growth Hormone: Monitor IGF-1 levels periodically (to guide dosing and avoid excessive elevation). Check thyroid function (GH can unmask hypothyroidism) and glucose/insulin (risk of hyperglycemia). Assess growth velocity every 3–6 months; bone age yearly. Screen for side effects: fundoscopic exam if headaches (intracranial hypertension), orthopedist check for SCFE if hip pain.
Anabolics (Oxandrolone): Monitor growth velocity and bone age (to avoid early closure). Regular liver function tests (transaminases). Lipid panel (HDL can drop). In girls, monitor virilization signs (voice changes, acne). Discontinue if significant androgenic effects appear.
Regulatory & Ethical Considerations
These therapies are highly regulated.
GH is FDA-approved for many growth disorders (GH deficiency, Turner, chronic renal failure, ISS, small for gestational age, Prader–Willi with restrictions). Prescribing GH for non-pathologic short stature (outside FDA indications) is not standard and controversial. Insurance coverage often requires height < –2.25 SDS (~1st percentile) and/or documented short stature disorders. Ethical debates center on “medical need vs enhancement” and psychosocial benefit.
FGFR3 Inhibitors: Vosoritide is FDA- and EMA-approved only for achondroplasia with open growth plates. Infigratinib is investigational. Using them for other short-stature children would be off-label/unapproved research. Orphan drug status for achondroplasia speeds approval for that condition, but prohibits non-indicated use.
Anabolic Steroids: Oxandrolone is not FDA-approved for short stature per se (though used off-label in Turner). Most anabolic steroids (testosterone derivatives) are controlled substances due to abuse potential. Prescribing them for height enhancement in adolescents raises significant ethical and legal issues. WADA (anti-doping) bans exogenous GH and AAS in sports; outside sports, unapproved use is not allowed. Clinically, ethical use is limited to specific disorders (e.g. oxandrolone in Turner, testosterone for true hypogonadism). Using AAS in healthy children for a few cm gain would be ethically unacceptable.
Broad ethics: All these interventions in adolescence must weigh benefit vs risk and consider psychosocial impact, equity (access often limited by cost), and long-term unknowns. Guidelines emphasize shared decision-making and highlight that height gain may not improve quality of life for all patients.
Interactions & Combination Therapy
No known pharmacologic antagonisms among GH, FGFR3 inhibitors, and anabolics, but effects may be additive or confounding:
GH + Anabolics: Commonly combined (e.g. Turner: GH + oxandrolone). Additive height gain (oxandrolone adds a few cm to GH alone). Monitor for synergistic side effects (e.g. insulin resistance from both GH and AAS).
FGFR3 Inhibitor + GH: Not standard. A child with achondroplasia on vosoritide usually isn’t GH deficient; adding GH is unlikely to greatly exceed effects of FGFR3 blockade. No trials to date.
FGFR3 Inhibitor + Anabolic: Also not described (achondroplasia patients are typically not given androgens for height). In practice, combination regimens are tailored by diagnosis (see flowchart below). Anecdotally, users discuss unproven “stacking” (e.g. GH + IGF-1 analogs + AAS) – such approaches lack evidence and carry high risk.
Gaps & Research Needs
Long-term Adult Height: For FGFR3 inhibitors (e.g. vosoritide), final adult height data are not yet available; ongoing trials must confirm that increased growth velocity translates into substantial height gain.
Non-ACH Short Stature: No good evidence for using FGFR3 inhibitors or AAS in normal short adolescents. Research is needed on any off-label growth-promoting therapies, but ethical boundaries are high.
Safety in Adolescence: Most data are in children; effects on puberty, bone health, metabolic profile into adulthood need study (especially for novel agents like FGFR3 inhibitors).
Optimal Regimens: The best dosing, timing and combinations (e.g. optimal age to start FGFR3 inhibitor; how long to use oxandrolone) requires more trials.
Quality of Life/Ethics: Better data on psychosocial outcomes of height interventions, and consensus on ethical use in borderline cases (e.g. “short normal” adolescents), would inform practice.
Anecdotal Forum Reports (unofficial)
User discussions on health/fitness forums emphasize limitations: most agree that genetics caps height and without deficiency or open plates, gains are modest. For example, one poster summarized: “HGH will NOT make you taller” unless you are GH-deficient. Another thread notes that “after growth plates are closed you are kinda fucked – even HGH ... will only boost final height by like an inch up to 3 inches if you’re lucky”. These reports (while non-scientific) reflect a common theme: attempts to “hack” height often underestimate biology. They underscore why medical authorities caution that height interventions work only within physiological growth limits.
Summary Table of Interventions
Intervention (Target)Mechanism (Growth Plate)Typical Dosing (Studies)Height Gain (Adult)Key Adverse EffectsEvidence (Level)
Vosoritide (FGFR3 inhibitor)<br>(achondroplasia)CNP analog→NPR-B →↓FGFR3 signaling15 µg/kg sc daily+1.6 cm/yr vs placebo (1 yr);<br>~+9 cm vs natural (4.5 yr)Injection-site reactions; transient hypotension; vomiting, ↑ALPRCTs (phase 3 in children); open-label extensions
Infigratinib (FGFR3 TK inhibitor)Oral FGFR1–3 blockade →↑chondrocyte growth~0.25 mg/kg po daily (max dose)+2.5 cm/yr AHV at 18 mo (highest dose) (z-score +0.54)Mild GI (nausea, vomit), headache; one case grade 1 hyperphosphatemiaPhase 2 trial (children 3–11); Phase 3 planned
Recombinant GH<br>(GH-deficiency, ISS, TS, SGA)↑IGF-1, ↑chondrocyte division in growth plate~0.2–0.35 mg/kg/week sc (dose↑ with weight)~4–9 cm extra vs untreated (dose-dependent);<br> often normalize to genetic target in GHDEdema, joint pain; metabolic (↑glucose, hypothyroid unmask); rare SCFE/pseudotumorMultiple RCTs/cohorts; high-level evidence in GHD; moderate in ISS
Oxandrolone (weak AAS)<br>(adjuvant in GH-treated TS)Androgen receptor→↑protein synthesis, ↑GH secretion; eventual ↑estrogen→fusion~0.03–0.05 mg/kg/day orally (used ages ~9–12)+2.7 cm final height vs GH alone in TurnerVirilization (voice deepening, acne); liver enzyme ↑; dyslipidemia; early epiphyseal closure
Executive Summary: New agents targeting growth-plate biology (e.g. FGFR3 inhibitors) and traditional therapies (growth hormone, androgens) have been explored to increase final adult height. FGFR3 inhibitors (vosoritide, infigratinib) work by blocking FGFR3 signaling to boost chondrocyte proliferation. In achondroplasia, vosoritide yields ~1.6–2.0 cm/year excess growth and ~9 cm extra over ~4.5 years (phase 2); infigratinib (oral) shows ~2.5 cm/yr gain at optimal dose. Human GH stimulates IGF-1 and growth plate activity; high-dose GH (0.3–0.4 mg/kg/week) in idiopathic short stature (ISS) can add ~4–9 cm to adult height, though gains tend not to exceed genetic potential. Anabolic steroids (e.g. oxandrolone) modestly improve height when added to GH (e.g. +2–3 cm in Turner syndrome) but cause virilizing effects and premature epiphyseal closure. All interventions must stop once growth plates fuse. Safety concerns are agent-specific: FGFR3 inhibitors can cause hypotension or metabolic shifts; GH therapy can trigger slipped capital femoral epiphysis or glucose intolerance; androgens carry hepatic, lipid and virilization risks. These treatments are approved only for defined conditions (e.g. GH deficiency, achondroplasia, Turner), not for non-pathologic short stature. Combining therapies (GH+anabolic in Turner; GH+GnRH analogs in puberty delay) is sometimes used. Baseline and periodic monitoring (bone age, IGF-1, lipids, BP, blood counts/liver tests) are needed. Major evidence gaps include long-term adult-height outcomes (especially for FGFR3 inhibitors) and effects in non-dwarfism short stature. Anecdotally, forum discussions stress that without growth-plate openness or deficiency, height gains are generally limited (often ≤ 2–3 inches total).
Mechanisms of Action
FGFR3 Inhibitors: FGFR3 normally suppresses endochondral bone growth. Achondroplasia is due to FGFR3 gain-of-function; inhibiting this pathway (by CNP analogues or FGFR3 tyrosine kinase inhibitors) lifts this brake. Vosoritide (CNP analog) activates natriuretic-peptide receptor B to reduce FGFR3 signaling. Infigratinib and similar drugs block the FGFR3 tyrosine kinase. The net effect is increased chondrocyte proliferation and height velocity.
Growth Hormone (hGH): Recombinant GH increases production of IGF-1 (especially in the liver), which stimulates chondrocyte proliferation in growth plates. GH also has direct effects on bone and cartilage. This axis is endogenous and GH’s anabolic effects on bone underlie its use in GH deficiency and other growth disorders.
Anabolic Steroids (Androgens): Androgens (e.g. testosterone derivatives) bind the androgen receptor to promote protein synthesis and growth. In prepubertal boys with delayed puberty, testosterone can trigger a growth spurt (via GH/IGF-1); in girls (e.g. Turner syndrome), weak androgens (oxandrolone) augment GH therapy. However, androgens are aromatized to estrogen, which accelerates epiphyseal fusion. Thus, androgens both stimulate and eventually terminate growth plate activity.
Efficacy Evidence (Final Height Gain)
Achondroplasia (FGFR3 inhibitors): Vosoritide trials (phase 3, 1 year) show ~1.6 cm mean height gain vs placebo (annualized velocity ~5.96 vs 4.22 cm/yr). Open-label extension data suggest ~9 cm extra height vs natural history over ~4.5 years. Long-term anecdotal reports (company press) cite ~13–14 cm over 8–10 years, but final height impact is still under study. Infigratinib (oral) in a recent NEJM trial (children 3–11 yr) increased height z-score by +0.54 over 18 months, corresponding to +2.5 cm/yr velocity at the highest dose. These are among the highest published gains in achondroplasia.
Idiopathic Short Stature / GH Deficiency (hGH): In GH-deficient children, GH therapy usually normalizes growth (adult height near target). In non-deficient short children, results vary. A large retrospective series (123 ISS children on 0.32 mg/kg/week) found average adult height ~–0.7 SDS (normalized) and a gain of ~9.5 cm (males) vs controls. Meta-analyses of RCTs in ISS show modest final height gains (typically ~4–6 cm over untreated). Gains correlate with dose and pubertal timing. In Turner syndrome, GH alone adds ~+8–10 cm. Combining GH with an anabolic (oxandrolone) further adds ~2–3 cm.
Anabolic (e.g. Oxandrolone): In Turner girls on GH, adding oxandrolone yields a mean final height increase of ~2.7 cm. Without GH (e.g. in constitutional delay), oxandrolone alone has no clear benefit on adult height. High-dose testosterone in prepubertal or pubertal boys can provoke a temporary growth spurt but generally leads to earlier closure and no net gain.
Safety Profiles & Adverse Effects
FGFR3 inhibitors: Vosoritide: Common adverse effects include injection-site reactions (erythema, pain, swelling) and transient hypotension. In trials, ~13% of vosoritide-treated children had brief blood pressure drops (vs 5% placebo); symptomatic dizziness/vomiting occurred in ~3%. Other events (vomiting, arthralgia) occurred in 5–10%. Long-term safety is still being defined, but trials report normal bone maturation and no serious cardiac or metabolic issues yet. Infigratinib: Generally mild side effects: headache, nausea, vomiting, limb pain were frequent. Hyperphosphatemia (a known effect of FGFR inhibitors) occurred in a few cases but was mild and manageable. No ocular or major bone toxicity was reported in 18 months.
hGH: Generally well tolerated in short-term. Common mild effects: joint pain, peripheral edema, injection-site pain. Elevated IGF-1 can cause benign intracranial hypertension (headache/blurred vision) in <1–2%. Slipped capital femoral epiphysis (SCFE) is a known rare complication (often with rapid growth, ~0.5–1% risk). GH can induce insulin resistance; new onset diabetes is very rare. Theoretical concerns about cancer risk have not been confirmed in long-term studies. Absolute contraindications: active malignancy, uncontrolled diabetes, intracranial hypertension. GH is also used cautiously in Prader–Willi (due to respiratory risk).
Anabolic steroids: Oxandrolone and other androgens cause virilizing effects: deepening voice, hirsutism, acne (noted in ~10–20% of girls on oxandrolone). Hepatotoxicity (elevated liver enzymes) is a concern with oral 17α-alkylated steroids. Lipid changes (↓HDL) and potential cardiovascular effects must be watched. Most critically, androgens cause premature epiphyseal closure through estrogen conversion, limiting final height. Therefore dosing must be carefully timed and often stopped before puberty. In Turner studies, oxandrolone was used only until age ~12–13 to avoid these effects.
Dosing Regimens
FGFR3 inhibitors: Vosoritide (Voxzogo): 15 µg/kg subcutaneously once daily (dose adjusted by weight every ~3–6 months). Continued daily dosing until growth plate closure. Phase 2 data suggest this dose in 5–10 yr-olds provides roughly +2 cm/year extra. Infigratinib: 0.25 mg/kg orally once daily (the highest dose in trials). Lower doses had less effect. Other FGFR3 compounds (TAK-536, etc) are experimental, dosing not established.
Human GH: Typical pediatric dosing is 0.16–0.3 mg/kg/week, divided into daily or nightly injections. In ISS or Turner, 0.3–0.35 mg/kg/week is often used to maximize height gain. Dosing is adjusted by weight as the child grows. Therapy usually continues until near-final height (bone age ~14–16 in girls, 16–18 in boys). GH must be prescribed under medical supervision.
Oxandrolone: In published Turner trials, oxandrolone was given ~0.03–0.05 mg/kg/day orally (5–10 mg/day) starting around age 9–11, added to GH. It was usually discontinued by mid-puberty. Other anabolic agents (testosterone, nandrolone, etc.) have no standard dosing for stature enhancement; anabolic steroid use outside guideline contexts is unsanctioned.
Timing & Growth Plate Status
All growth-promoting therapies require open epiphyses. Treatment is generally only effective while the physes are active. In practice:
Assess bone age by X-ray: if bone age is significantly less than chronological, there may be more growth potential.
FGFR3 inhibitors: Indicated when growth plates are open (FDA label: ages ≥5 with open plates). Expert consensus says “maximize time” by starting as early as possible and continue until plates fuse.
GH/Anabolics: Similarly, begun in childhood or early puberty. For example, in Turner syndrome, GH±oxandrolone is typically started at ages 6–12 and stopped when growth near completion.
Pubertal status: High estrogen/testosterone accelerates closure. Therapies like GnRH analogs (not FGFR3/GH/anabolic but worth noting) can delay puberty to prolong growth. If puberty is advanced, the window narrows. Adolescents (e.g. ≥15 yr) with near-fused plates may gain only a few cm at most. In short, once growth plates are closed, height gain >2–3 cm is highly unlikely.
Safety Monitoring
FGFR3 inhibitors (Vosoritide, etc.): Baseline and periodic blood pressure (risk of hypotension), and growth velocity/height measurements every 3–6 months. Monitor height/weight and adjust dose accordingly. Annual bone age X-ray helps track progress. Lab tests: No mandated labs for vosoritide aside from BP, but check chemistries if clinical (infigratinib needs phosphate monitoring due to potential hyperphosphatemia).
Growth Hormone: Monitor IGF-1 levels periodically (to guide dosing and avoid excessive elevation). Check thyroid function (GH can unmask hypothyroidism) and glucose/insulin (risk of hyperglycemia). Assess growth velocity every 3–6 months; bone age yearly. Screen for side effects: fundoscopic exam if headaches (intracranial hypertension), orthopedist check for SCFE if hip pain.
Anabolics (Oxandrolone): Monitor growth velocity and bone age (to avoid early closure). Regular liver function tests (transaminases). Lipid panel (HDL can drop). In girls, monitor virilization signs (voice changes, acne). Discontinue if significant androgenic effects appear.
Regulatory & Ethical Considerations
These therapies are highly regulated.
GH is FDA-approved for many growth disorders (GH deficiency, Turner, chronic renal failure, ISS, small for gestational age, Prader–Willi with restrictions). Prescribing GH for non-pathologic short stature (outside FDA indications) is not standard and controversial. Insurance coverage often requires height < –2.25 SDS (~1st percentile) and/or documented short stature disorders. Ethical debates center on “medical need vs enhancement” and psychosocial benefit.
FGFR3 Inhibitors: Vosoritide is FDA- and EMA-approved only for achondroplasia with open growth plates. Infigratinib is investigational. Using them for other short-stature children would be off-label/unapproved research. Orphan drug status for achondroplasia speeds approval for that condition, but prohibits non-indicated use.
Anabolic Steroids: Oxandrolone is not FDA-approved for short stature per se (though used off-label in Turner). Most anabolic steroids (testosterone derivatives) are controlled substances due to abuse potential. Prescribing them for height enhancement in adolescents raises significant ethical and legal issues. WADA (anti-doping) bans exogenous GH and AAS in sports; outside sports, unapproved use is not allowed. Clinically, ethical use is limited to specific disorders (e.g. oxandrolone in Turner, testosterone for true hypogonadism). Using AAS in healthy children for a few cm gain would be ethically unacceptable.
Broad ethics: All these interventions in adolescence must weigh benefit vs risk and consider psychosocial impact, equity (access often limited by cost), and long-term unknowns. Guidelines emphasize shared decision-making and highlight that height gain may not improve quality of life for all patients.
Interactions & Combination Therapy
No known pharmacologic antagonisms among GH, FGFR3 inhibitors, and anabolics, but effects may be additive or confounding:
GH + Anabolics: Commonly combined (e.g. Turner: GH + oxandrolone). Additive height gain (oxandrolone adds a few cm to GH alone). Monitor for synergistic side effects (e.g. insulin resistance from both GH and AAS).
FGFR3 Inhibitor + GH: Not standard. A child with achondroplasia on vosoritide usually isn’t GH deficient; adding GH is unlikely to greatly exceed effects of FGFR3 blockade. No trials to date.
FGFR3 Inhibitor + Anabolic: Also not described (achondroplasia patients are typically not given androgens for height). In practice, combination regimens are tailored by diagnosis (see flowchart below). Anecdotally, users discuss unproven “stacking” (e.g. GH + IGF-1 analogs + AAS) – such approaches lack evidence and carry high risk.
Gaps & Research Needs
Long-term Adult Height: For FGFR3 inhibitors (e.g. vosoritide), final adult height data are not yet available; ongoing trials must confirm that increased growth velocity translates into substantial height gain.
Non-ACH Short Stature: No good evidence for using FGFR3 inhibitors or AAS in normal short adolescents. Research is needed on any off-label growth-promoting therapies, but ethical boundaries are high.
Safety in Adolescence: Most data are in children; effects on puberty, bone health, metabolic profile into adulthood need study (especially for novel agents like FGFR3 inhibitors).
Optimal Regimens: The best dosing, timing and combinations (e.g. optimal age to start FGFR3 inhibitor; how long to use oxandrolone) requires more trials.
Quality of Life/Ethics: Better data on psychosocial outcomes of height interventions, and consensus on ethical use in borderline cases (e.g. “short normal” adolescents), would inform practice.
Anecdotal Forum Reports (unofficial)
User discussions on health/fitness forums emphasize limitations: most agree that genetics caps height and without deficiency or open plates, gains are modest. For example, one poster summarized: “HGH will NOT make you taller” unless you are GH-deficient. Another thread notes that “after growth plates are closed you are kinda fucked – even HGH ... will only boost final height by like an inch up to 3 inches if you’re lucky”. These reports (while non-scientific) reflect a common theme: attempts to “hack” height often underestimate biology. They underscore why medical authorities caution that height interventions work only within physiological growth limits.
Summary Table of Interventions
Intervention (Target)Mechanism (Growth Plate)Typical Dosing (Studies)Height Gain (Adult)Key Adverse EffectsEvidence (Level)
Vosoritide (FGFR3 inhibitor)<br>(achondroplasia)CNP analog→NPR-B →↓FGFR3 signaling15 µg/kg sc daily+1.6 cm/yr vs placebo (1 yr);<br>~+9 cm vs natural (4.5 yr)Injection-site reactions; transient hypotension; vomiting, ↑ALPRCTs (phase 3 in children); open-label extensions
Infigratinib (FGFR3 TK inhibitor)Oral FGFR1–3 blockade →↑chondrocyte growth~0.25 mg/kg po daily (max dose)+2.5 cm/yr AHV at 18 mo (highest dose) (z-score +0.54)Mild GI (nausea, vomit), headache; one case grade 1 hyperphosphatemiaPhase 2 trial (children 3–11); Phase 3 planned
Recombinant GH<br>(GH-deficiency, ISS, TS, SGA)↑IGF-1, ↑chondrocyte division in growth plate~0.2–0.35 mg/kg/week sc (dose↑ with weight)~4–9 cm extra vs untreated (dose-dependent);<br> often normalize to genetic target in GHDEdema, joint pain; metabolic (↑glucose, hypothyroid unmask); rare SCFE/pseudotumorMultiple RCTs/cohorts; high-level evidence in GHD; moderate in ISS
Oxandrolone (weak AAS)<br>(adjuvant in GH-treated TS)Androgen receptor→↑protein synthesis, ↑GH secretion; eventual ↑estrogen→fusion~0.03–0.05 mg/kg/day orally (used ages ~9–12)+2.7 cm final height vs GH alone in TurnerVirilization (voice deepening, acne); liver enzyme ↑; dyslipidemia; early epiphyseal closure
